Novartis, Monte Rosa Ink Up To $5.7B 'Molecular Glue' Deal
By Al Barbarino · September 15, 2025, 12:39 PM EDT
Novartis is placing a potential $5.7 billion bet on Monte Rosa Therapeutics, a clinical-stage biotech company, to develop new treatments for immune-related diseases, Monte Rosa said on Monday. ...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login